{"DataElement":{"publicId":"7055127","version":"1","preferredName":"Acute Myeloid Leukemia Or Myelodysplastic Syndrome Morphologic Response Status","preferredDefinition":"The disease status or response to treatment of acute myeloid leukemia or myelodysplastic syndrome based on a morphologic evaluation.","longName":"AMLMDSMS","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"7050189","version":"1","preferredName":"Disease Response Domain Acute Myeloid Leukemia Or Myelodysplastic Syndrome Morphologic Response","preferredDefinition":"A domain for disease response evaluations._A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)_An evaluation of the morphologic response of the disease to the therapy.","longName":"6608777v1.0:7050187v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6608777","version":"1","preferredName":"Disease Response Domain","preferredDefinition":"A domain for disease response evaluations.","longName":"C107097","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response Domain","conceptCode":"C107097","definition":"A domain for disease response evaluations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6DD03A-0CB9-71AE-E053-F662850AB42C","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"ONEDATA","dateModified":"2019-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7050187","version":"1","preferredName":"Acute Myeloid Leukemia Or Myelodysplastic Syndrome Morphologic Response","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001):An evaluation of the morphologic response of the disease to the therapy.","longName":"C3171:C37998:C3247:C123625","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Morphologic Response","conceptCode":"C123625","definition":"An evaluation of the morphologic response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DD1C22-78A1-57A1-E053-F662850AF66D","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-08","modifiedBy":"ONEDATA","dateModified":"2019-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"96DD1C22-78B2-57A1-E053-F662850AF66D","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-08","modifiedBy":"KUMMEROA","dateModified":"2020-06-17","changeDescription":"Released. AK 2020-6-10; Created for CDSIC aligned NCI Standard CRFs. ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3854966","version":"1","preferredName":"AML/MDS Morphologic Response Status","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"AMLMDS_MORPH_RESP_ST","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Morphologic Complete Response with Incomplete Blood Count Recovery (CRi)","valueDescription":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","ValueMeaning":{"publicId":"3854971","version":"1","preferredName":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","longName":"3854971","preferredDefinition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Remission with Incomplete Blood Count Recovery","conceptCode":"C123596","definition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86DA-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E485A8-0319-C9B7-E040-BB89AD4349BE","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Complete Remission (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4EFEF9F-C587-E214-E040-BB89AD43433D","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-27","modifiedBy":"ONEDATA","dateModified":"2013-08-27","deletedIndicator":"No"},{"value":"Not Evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3DF4512-8653-A83E-E040-BB89AD431C6D","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","deletedIndicator":"No"},{"value":"Leukemic Transformation","valueDescription":"Leukemic Cell Transformation","ValueMeaning":{"publicId":"3854967","version":"1","preferredName":"Leukemic Cell Transformation","longName":"3854967","preferredDefinition":"Malignant hematopoietic cell originating in the clonal proliferation of myeloid or lymphoid precursor that undergoes an aberrant and poorly regulated process of organogenesis resulted in arrested maturation and cell capacity for unlimited self-renewal.: The conversion of a cell from a normal phenotype, which undergoes a limited number of mitotic divisions, into an aberrant phenotype that is immortal and divides indefinitely. Transformed cells no longer retain cell-cycle checkpoints and may ultimately become malignant cancer cells via additional genetic mutations, or damaging environmental events.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemic Cell","conceptCode":"C25553","definition":"Malignant hematopoietic cell originating in the clonal proliferation of myeloid or lymphoid precursor that undergoes an aberrant and poorly regulated process of organogenesis resulted in arrested maturation and cell capacity for unlimited self-renewal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transformation","conceptCode":"C17212","definition":"The conversion of a cell from a normal phenotype, which undergoes a limited number of mitotic divisions, into an aberrant phenotype that is immortal and divides indefinitely. Transformed cells no longer retain cell-cycle checkpoints and may ultimately become malignant cancer cells via additional genetic mutations, or damaging environmental events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-866B-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3DF4512-8684-A83E-E040-BB89AD431C6D","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","deletedIndicator":"No"},{"value":"Morphologic Relapse","valueDescription":"Morphologic Finding Recurrent Disease","ValueMeaning":{"publicId":"3854968","version":"1","preferredName":"Morphologic Finding Recurrent Disease","longName":"3854968","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-8691-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3DF4512-86AA-A83E-E040-BB89AD431C6D","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07B3B040-C8F5-FD7B-E050-BB89AD433BF1","beginDate":"2014-11-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-12","modifiedBy":"ONEDATA","dateModified":"2014-11-12","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Relapse","ValueMeaning":{"publicId":"2857244","version":"1","preferredName":"Relapse","longName":"2857244","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C18265","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66219F23-0990-8382-E040-BB89AD432D5C","latestVersionIndicator":"Yes","beginDate":"2009-03-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-11-17","changeDescription":null,"administrativeNotes":"2023.3.9 Added Alt VM per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06FECA4E-7E14-9714-E050-BB89AD432ED0","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"ONEDATA","dateModified":"2014-11-03","deletedIndicator":"No"},{"value":"Refractory Disease","valueDescription":"Refractory Disease","ValueMeaning":{"publicId":"4571271","version":"1","preferredName":"Refractory Disease","longName":"4571271","preferredDefinition":"A disease that resists treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Disease","conceptCode":"C39752","definition":"A disease that resists treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06FECA4E-7E2B-9714-E050-BB89AD432ED0","latestVersionIndicator":"Yes","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06FECA4E-7E44-9714-E050-BB89AD432ED0","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"ONEDATA","dateModified":"2014-11-03","deletedIndicator":"No"},{"value":"Progressive Disease (PD)","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"2559908","version":"1","preferredName":"Progressive Disease","longName":"2559908","preferredDefinition":"Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B711-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeDescription":"Manually Curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06FECA4E-7E58-9714-E050-BB89AD432ED0","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"ONEDATA","dateModified":"2014-11-03","deletedIndicator":"No"},{"value":"Not Assessed","valueDescription":"No Assessment","ValueMeaning":{"publicId":"2768467","version":"1","preferredName":"No Assessment","longName":"2768467","preferredDefinition":"The non-affirmative response to a question.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52C71733-4814-2BF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06FECA4E-80CC-9714-E050-BB89AD432ED0","beginDate":"2013-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"ONEDATA","dateModified":"2014-11-03","deletedIndicator":"No"},{"value":"Complete Response with incomplete platelet recovery (CRp)","valueDescription":"Complete Response with Incomplete Platelet Recovery","ValueMeaning":{"publicId":"4639742","version":"1","preferredName":"Complete Response with Incomplete Platelet Recovery","longName":"4639742","preferredDefinition":"The disappearance of all signs of cancer in response to treatment, accompanied by incomplete platelet recovery (platelet count is less than 100,000/uL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response with Incomplete Platelet Recovery","conceptCode":"C118794","definition":"The disappearance of all signs of cancer in response to treatment, accompanied by incomplete platelet recovery (platelet count is less than 100,000/uL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A711901-5A69-D5F1-E050-BB89AD431F21","latestVersionIndicator":"Yes","beginDate":"2014-12-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-17","modifiedBy":"KUMMEROA","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":"2023.3.22 Alt VM added per ticket request CADSR0002191. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A711901-5A82-D5F1-E050-BB89AD431F21","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-17","modifiedBy":"ONEDATA","dateModified":"2014-12-17","deletedIndicator":"No"},{"value":"Partial Remission (PR)","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3854969","version":"1","preferredName":"Partial Remission","longName":"3854969","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86B4-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A56948B-6A88-682D-E053-F662850A9689","beginDate":"2017-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-29","modifiedBy":"ONEDATA","dateModified":"2017-09-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3865327","version":"1","preferredName":"Morphologic Finding Response Status","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C35867:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4E2F160-F279-E72E-E040-BB89AD430752","latestVersionIndicator":"Yes","beginDate":"2013-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3DF4512-863C-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"TAYLORT","dateModified":"2017-09-29","changeDescription":"9/29/17 tt re-added Partial Response PV.   9/28/17 tt removed Partial response (PR) from PVs. 8/23/17 jk added registration status and CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6921971","version":"1","longName":"CDISC Aligned Collection CDEs","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"7318366","version":"1","longName":"Response - CDISC Aligned","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Morphologic status (AML/MDS)","type":"Preferred Question Text","description":"Morphologic status (AML/MDS)","url":null,"context":"NCI Standards"},{"name":"CDISC Aligned NCI Standard Equivalent CDE","type":"CDISC Note","description":"This data element is to be used for CDISC aligned data collection in place of CDE 3855562 from the original NCI Standard CRF Template.","url":null,"context":"NCI Standards"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"97437E52-7D79-4A87-E053-F662850AEA90","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-13","modifiedBy":"GDEEN","dateModified":"2023-02-13","changeDescription":"Released. AK 2020-6-17; Created for CDSIC aligned NCI Standard CRFs. ghd","administrativeNotes":"02.13.23_Set Reg Status to Standard for all CDISC Aligned content_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}